These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32869146)

  • 1. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?
    Dikilitas M
    J Gastrointest Cancer; 2020 Dec; 51(4):1193-1196. PubMed ID: 32869146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.
    Pinato DJ; Fessas P; Sapisochin G; Marron TU
    Hepatology; 2021 Jul; 74(1):483-490. PubMed ID: 33369758
    [No Abstract]   [Full Text] [Related]  

  • 3. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
    Akateh C; Black SM; Conteh L; Miller ED; Noonan A; Elliott E; Pawlik TM; Tsung A; Cloyd JM
    World J Gastroenterol; 2019 Jul; 25(28):3704-3721. PubMed ID: 31391767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
    Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
    Mohr R; Jost-Brinkmann F; Özdirik B; Lambrecht J; Hammerich L; Loosen SH; Luedde T; Demir M; Tacke F; Roderburg C
    Front Immunol; 2021; 12():652172. PubMed ID: 33859646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.
    Nakazawa M; Fang M; Vong T; Zorzi J; Griffith P; Anders RA; Oshima K; Kim AK; Laurin J; Lafaro KJ; Shubert CR; Burns WR; He J; Burkhart RA; Philosophe B; Meyer J; Liddell RP; Georgiades C; Hong K; Ho WJ; Baretti M; Strauss AT; Yarchoan M
    Cancer Res Commun; 2024 Aug; 4(8):2123-2132. PubMed ID: 39142659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
    Haber PK; Puigvehí M; Castet F; Lourdusamy V; Montal R; Tabrizian P; Buckstein M; Kim E; Villanueva A; Schwartz M; Llovet JM
    Gastroenterology; 2021 Sep; 161(3):879-898. PubMed ID: 34126063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook.
    Sahin IH; Khalil L; Millett R; Kaseb A
    Chin Clin Oncol; 2021 Feb; 10(1):7. PubMed ID: 33440948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma.
    Meng M; Li W; Yang X; Huang G; Wei Z; Ni Y; Han X; Wang J; Ye X
    J Cancer Res Ther; 2020; 16(2):327-334. PubMed ID: 32474520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait?
    Ersan V; Barut B; Yilmaz S
    J Gastrointest Cancer; 2020 Dec; 51(4):1152-1156. PubMed ID: 32856230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TATI modality: A new perspective on the treatment of advanced hepatocellular carcinoma.
    Li X; Liang P; Ye X
    J Cancer Res Ther; 2020 Sep; 16(5):957-959. PubMed ID: 33004734
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.
    Victor DW; Monsour HP; Boktour M; Lunsford K; Balogh J; Graviss EA; Nguyen DT; McFadden R; Divatia MK; Heyne K; Ankoma-Sey V; Egwim C; Galati J; Duchini A; Saharia A; Mobley C; Gaber AO; Ghobrial RM
    Transplantation; 2020 Jan; 104(1):113-121. PubMed ID: 31233480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for hepatocellular carcinoma after curative treatment.
    Jeng WJ; Lin CC; Chen WT; Sheen IS; Lin CY; Lin SM
    Dig Dis; 2014; 32(6):747-54. PubMed ID: 25376293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Radiation Lobectomy and Immunotherapy for Angioinvasive HCC Resulting in Complete Pathologic Response.
    Liou H; Mody K; Boyle AW; Keaveny AP; Croome KP; Burns JM; Harnois DM; Patel TC; Toskich B
    Hepatology; 2021 Jul; 74(1):525-527. PubMed ID: 33615518
    [No Abstract]   [Full Text] [Related]  

  • 19. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.
    Zhou H; Song T
    Biosci Trends; 2021 Jul; 15(3):155-160. PubMed ID: 34039818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma.
    Urquijo-Ponce JJ; Alventosa-Mateu C; Latorre-Sánchez M; Castelló-Miralles I; Diago M
    World J Gastroenterol; 2024 May; 30(19):2512-2522. PubMed ID: 38817666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.